Review of Clinical Pharmacology and Pharmacokinetics – International Edition Volume 38 (2024) – Supplementary Issue 2

Open Access Research

Molecular study of KRAS mutations in Iraqi patients with gastrointestinal tract cancer

Hajir B. Aljaryan¹, Ataa Khalil Al-Shamari^1,*, Taif Hussein Al-Ameedy¹, Amal Talib Al Sa’ady¹, Samir Azzat Malik Hussain²
¹Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Hillah, Iraq
²College of Pharmacy, Al-Mustaqbal University, Hillah, Iraq

*Corresponding author: Ataa Khalil Al-Shamari, Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Hillah, Iraq; Tel.: +964-(0)7722236034
E-mail: pharm.ataa.khalil@uobabylon.edu.iq

Download PDF

Published: 5 May 2024; https://doi.org/10.61873/UUXZ2461

Abstract
Gastrointestinal cancers, including stomach, liver, oesophageal, pancreatic, and colorectal cancers, represent more than a quarter of all cancers. Many abnormal gene expressions and dysregulated signalling pathways have been found in human cancer. Cancer often has activating mutations of the KRAS (Kirsten rat sarcoma virus) oncogene. Fifty blood samples from gastrointestinal cancer patients were gathered from the Merjan Teaching Hospital in Babylon, Iraq, and were used for a case-control study in the Oncology Center. According to the results, the most common cancers were found in the colon (29%), followed by the liver (27%), pancreas (19%), stomach (13%), and other (12%). In this work, we evaluated the distribution of KRAS mutations across the gastrointestinal tract. Sequencing data revealed a significant regional difference in the frequency of KRAS mutations, while the alignment results revealed the presence of six variations in the analysed samples when compared with the referring reference DNA sequences. Six highly interesting nucleic acid polymorphisms were detected in the investigated samples. When combined with additional carcinogenic markers such as the patient sex, age, consistent molecular subtypes, and tumour stage, KRAS mutation is not the deterministic carcinogenic factor for gastrointestinal malignancies.

Keywords: polymorphism, KRAS gene, gastrointestinal tract cancer, protein folding, mutation

Please cite as:
Aljaryan H. B., Al-Shamari A. K., Al-Ameedy T. H., Al Sa’ady A. T., Hussain S. A. M. A. Molecular study of KRAS mutations in Iraqi patients with gastrointestinal tract cancer. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38 (Sup2): 73-76 (2024). https://doi.org/10.61873/UUXZ2461